Androgen Deprivation Therapy (ADT)
Chemical Castration in Prostate Cancer - The Opposite of TRT
Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- FDA Approved (GnRH agonists/antagonists; e.g., leuprolide 1985, degarelix 2008)
Reference only. Not medical advice.
What can go wrong
ADT causes hot flashes, loss of libido and erectile function, fatigue, muscle loss, osteoporosis and fracture risk, metabolic syndrome and diabetes risk, gynecomastia, mood and cognitive effects, and a debated increase in cardiovascular events (more associated with agonists). Bone density and cardiometabolic monitoring are standard.
This is something to take to a clinician. The Atlas can tell you what is known about androgen deprivation therapy (adt) in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Androgen deprivation therapy (ADT) treats advanced or high-risk prostate cancer by lowering testosterone to castrate levels - the modern, reversible-by-injection equivalent of surgical castration. GnRH agonists (leuprolide) and antagonists (degarelix, relugolix) suppress the pituitary-gonadal axis; antagonists avoid the initial testosterone surge ('flare') of agonists. By starving androgen-dependent tumors, ADT extends survival, but the systemic loss of testosterone produces hot flashes, loss of libido and erectile function, fatigue, bone loss, metabolic change, and a debated cardiovascular risk signal.
The therapeutic mirror image of TRT: deliberately driving testosterone to castrate levels.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
GnRH agonists, after an initial surge, downregulate pituitary GnRH receptors and shut off luteinizing hormone, collapsing testicular testosterone production. GnRH antagonists block the receptor directly, achieving rapid castrate levels without flare. With androgen withdrawn, androgen-dependent prostate cancer cells undergo apoptosis or growth arrest. The same androgen withdrawal that treats the tumor produces the systemic hypogonadal syndrome.
Why ADT is the mirror of TRT
ADT and TRT are physiological opposites operating on the same axis, which is why ADT is the natural-experiment counterpart in the testosterone debate. The symptom list of ADT - low libido, ED, fatigue, hot flashes, bone loss, adverse metabolic shifts - is essentially severe hypogonadism induced on purpose. Some analyses link GnRH agonists to increased cardiovascular events versus ADT-naive patients, and GnRH antagonists have been studied for a potentially more favorable cardiovascular profile, though this remains debated.
Safety in detail
Androgen deprivation therapy produces profound systemic physiological effects and requires oncologic supervision with bone, metabolic, and cardiovascular monitoring. It is a cancer treatment, not a lifestyle intervention.
What it does to fertility
ADT suppresses spermatogenesis and causes infertility while active; recovery after discontinuation is variable and not guaranteed. Sperm banking before treatment should be discussed where fertility matters.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Testosterone (confirm castrate level)
- PSA response
- Bone mineral density (DEXA)
- Lipids / glucose / HbA1c
- Cardiovascular risk assessment
What people get wrong
Often saidADT side effects are minor inconveniences
ActuallyADT induces a profound hypogonadal state - bone loss, metabolic syndrome, cardiovascular risk signals, and major sexual and cognitive effects are well documented and need active management.
Often saidChemical castration is permanent
ActuallyMedical ADT is generally reversible if stopped, though testosterone recovery can be slow or incomplete, especially after prolonged use or in older men.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
Set against the alternatives
Versus surgical orchiectomy, medical ADT is reversible and avoids surgery but is costly and ongoing. Agonists are long-established but cause a testosterone flare requiring anti-androgen cover in high-burden disease; antagonists avoid flare and may carry a different cardiovascular profile. Intermittent ADT can reduce side-effect burden in selected patients.
At a glance
- Goal
- Testosterone to castrate level (<50 ng/dL)
- Agonists
- Leuprolide, goserelin (cause initial flare)
- Antagonists
- Degarelix, relugolix (no flare)
- Core effects
- Hot flashes, low libido, ED, bone loss, metabolic change
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Androgen Deprivation Therapy (ADT). A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
ADT cardiovascular toxicity SEER analyses2000s-2010s
GnRH agonists associated with increased coronary artery disease, myocardial infarction, and sudden cardiac death vs ADT-naive men
GnRH antagonist vs agonist cardiovascular signal (e.g., HERO/relugolix context)2020
Antagonist therapy studied for a potentially lower cardiovascular event signal, though comparisons remain debated